Indication
Hypertriglyceridemia
RAG rating
Red
Document type
Decision document
Place
Hertfordshire and West Essex ICB
Output type
Pharmacy / Prescribing
Document
Download

Icosapent ethyl

HERTFORDSHIRE AND WEST ESSEX AREA PRESCRIBING COMMITTEE (HWE APC)

Icosapent ethyl to reduce the risk of cardiovascular events in adult statin treated patients at high cardiovascular risk with elevated triglycerides

RED

Recommended for restricted prescribing by specialist only

Not recommended for primary care prescribing

Name generic (trade) Icosapent ethyl

What it is a stable ethyl ester of the omega-3 fatty acid, eicosapentaenoic acid

Indication to reduce the risk of cardiovascular events in adult statin treated patients at high cardiovascular risk with elevated triglycerides

Date decision last revised September 2022

Decision status Interim

NICE / SMC Guidance NICE TA 805 - recommended

HWE APC recommendation:

Icosapent ethyl is recommended as an option for reducing the risk of cardiovascular events in adults if they have a high risk of cardiovascular events and raised fasting triglycerides (1.7 mmol/litre or above) and are

taking statins, in adults in line with the recommendations in TA805.

RED STATUS*:

- NOT RECOMMENDED FOR PRIMARY CARE PRESCRIBING.

- RECOMMENDED FOR RESTRICTED PRESCRIBING BY SPECIALISTS

* Prescribing RAG recommendation to be reviewed at a future HWE APC meeting and pending experience in use from specialists. Side effect profile includes, but not limited to, increased incidence of AF, pulmonary oedema and bleeding related events.

 

NICE TA 805 recommendations:

Icosapent ethyl is recommended as an option for reducing the risk of cardiovascular events in adults. It is recommended if they have a high risk of cardiovascular events and raised fasting triglycerides (1.7 mmol/litre or above) and are taking statins, but only if they have:

  • established cardiovascular disease (secondary prevention), defined as a history of any of the following:
  • acute coronary syndrome (such as myocardial infarction or unstable angina needing hospitalisation)
  • coronary or other arterial revascularisation procedures
  • coronary heart disease
  • ischaemic stroke
  • peripheral arterial disease, and

 

AND low-density lipoprotein cholesterol (LDL‑C) levels above 1.04 mmol/litre and below or equal to 2.60 mmol/litre.

 Review date: The recommendation is based upon the evidence available at the time of publication. This recommendation will be reviewed upon request in the light of new evidence becoming available


Review date: The recommendation is based upon the evidence available at the time of publication. This recommendation will be reviewed upon request in the light of new evidence becoming available

Back